More precisely, immune cold ccRCC with mutated PBRM1 and immune hot tumors with del(9p21.3) have retrospectively been shown to predict superior responses to anti-PD1 blockade [17]. The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.